| Field | Specification |
|---|---|
| UniProt # | |
| Applications | |
| Sensitivity | |
| Detection range | |
| Detection method | |
| Assay time | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
This ELISA kit applies to the in vitro quantitative determination of Human IP-10/CXCL10 concentrations in serum, plasma and other biological fluids.
Assay Principle
This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human IP-10/CXCL10. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human IP-10/CXCL10 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human IP-10/CXCL10, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human IP-10/CXCL10. You can calculate the concentration of Human IP-10/CXCL10 in the samples by comparing the OD of the samples to the standard curve.
Performance Specifications
| Sensitivity | 4.69 pg/mL |
|---|---|
| Detection Range | 7.81-500 pg/mL |
| Total Assay Time | 3 h 30 min |
| Compatible Sample Types | Serum, plasma and other biological fluids |
| Species Reactivity | Human |
| Detection Method | Sandwich |
| Precision (CV) | Both intra-CV and inter-CV are < 10%. |
| Recovery Rate | 80%-120% |
| Storage | 2-8℃,12 months |
✓ Research-Grade Validation
Specificity
This kit recognizes Human IP-10/CXCL10 in samples. No significant cross-reactivity or interference between Human IP-10/CXCL10 and analogues was observed
Safety & Regulatory
Handle reagents in accordance with institutional biosafety guidelines. Refer to the Safety Data Sheet (SDS) for complete hazard and handling information. Contains components that may require special disposal procedures per local regulations.
This kit is validated for use with Serum, plasma and other biological fluids. For unlisted matrices (e.g., tissue lysate, urine), perform a spike-and-recovery experiment to confirm assay performance before generating reportable data. Sample dilution in the kit's provided diluent is recommended to minimize matrix interference.
The minimum detectable concentration (sensitivity) of this kit is 4.69 pg/mL. Values below this threshold should be reported as below the limit of detection (<LOD) and should not be extrapolated from the standard curve.
The total assay time from sample addition to absorbance reading is approximately 3 h 30 min, including all incubation, wash, and substrate steps. Hands-on time is typically 1–2 hours; most steps involve passive plate incubation. Plan the assay as a single uninterrupted session for best results.
Standard components of this Sandwich ELISA Kit typically include: pre-coated microplate (96-well strip format), lyophilized or liquid recombinant IP-10;CXCL10 standard, detection antibody, streptavidin-HRP conjugate, TMB substrate, stop solution, wash buffer concentrate, and sample/standard diluent. Refer to the kit insert or datasheet for the exact component list and storage requirements.
This kit uses colorimetric (TMB/HRP) detection and requires a standard microplate absorbance reader capable of measuring at 450 nm. A reference wavelength of 570 nm or 630 nm is recommended to reduce background. No specialized fluorescence or luminescence reader is needed. Ensure the instrument is calibrated and the plate is clean and free of condensation before reading.
Tissue samples may contain endogenous or exogenous proteases during processing, leading to degradation of extracted proteins. Therefore, it's necessary to add protease inhibitors during processing to ensure the integrity of target proteins. If customers can keep samples cold and handle them quickly during processing, omitting the protease inhibitor may not have a significant effect. After preparation, samples should be tested promptly or immediately aliquoted and frozen at -20°C or -80°C.
What is the range of enzyme activity of your IL-2 freeze-dried powder
What is the principle of adding stop solution to stop color reaction in ELISA experiment?
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Immune-related deubiquitylation spectrum of microsatellite stability colorectal cancer reveals USP7 as a potential immunotherapeutic target (2025) Molecular Cancer. 10.1186/s12943-025-02502-8
Synovium-On-A-Chip: Simulating the Microenvironment of the Rheumatoid Arthritis Synovium via Multicell Interactions to Target Fibroblast-Like Synoviocytes (2025) Advanced Science. 10.1002/advs.202511945
A SCID mouse-human lung xenograft model of SARS-CoV-2 infection (2021) Theranostics. 10.7150/thno.58321
Multiomics integration analysis identifies tumor cell-derived MIF as a therapeutic target and potentiates anti-PD-1 therapy in osteosarcoma (2025) Journal for ImmunoTherapy of Cancer. 10.1136/jitc-2024-011091
Clofarabine induces tumor cell apoptosis, GSDME-related pyroptosis, and CD8+ T-cell antitumor activity via the non-canonical P53/STING pathway (2025) Journal for ImmunoTherapy of Cancer. 10.1136/jitc-2024-010252
Mitochondrial DNA release via VDAC1 in keratinocytes: a key driver of innate immunity and vitiligo pathogenesis (2026) Cell Death & Disease. 10.1038/s41419-026-08585-5
VDAC1 oligomerization-mediated mtDNA release under sublethal oxidative stress: A novel inflammatory mechanism in vitiligo (2025) FREE RADICAL BIOLOGY AND MEDICINE. 10.1016/j.freeradbiomed.2025.09.018
Pathogenic Roles of CXCL10 in Experimental Autoimmune Prostatitis by Modulating Macrophage Chemotaxis and Cytokine Secretion (2021) Frontiers in Immunology. 10.3389/fimmu.2021.706027
AARS1-mediated lactylation of STAT1 drives immune evasion (2026) Cell Reports. 10.1016/j.celrep.2026.117094
ZFP36L1 promotes non-small cell lung cancer progression under hypoxia by modulating CXCL9:SPP1 polarity: A single-cell transcriptomic study (2026) Clinical and Translational Medicine. 10.1002/ctm2.70642
Inflammation-Driven Secretion Potential Is Upregulated in Osteoarthritic Fibroblast-Like Synoviocytes (2022) INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 10.3390/ijms231911817
Cytokine concentration in peripheral blood of patients with childhood obesity (2025) Frontiers in Immunology. 10.3389/fimmu.2025.1606375
BAP1 mutations inhibit the NF-κB signaling pathway to induce an immunosuppressive microenvironment in uveal melanoma (2023) MOLECULAR MEDICINE. 10.1186/s10020-023-00713-7
Activation of the STING-IRF3 pathway involved in psoriasis with diabetes mellitus (2022) JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 10.1111/jcmm.17236
CXCL10 modulates airway inflammation in asthma via Sirt3-dependent macrophage homeostasis (2025) LIFE SCIENCES. 10.1016/j.lfs.2025.123849
Leptin correlates with monocytes activation and severe condition in COVID-19 patients (2021) JOURNAL OF LEUKOCYTE BIOLOGY. 10.1002/JLB.5HI1020-704R
NLRP3 regulates CIITA/MHC II axis and interferon-γ-inducible chemokines in Malassezia globosa-infected keratinocytes (2023) MYCOSES. 10.1111/myc.13680
A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer (2024) INTERNATIONAL IMMUNOPHARMACOLOGY. 10.1016/j.intimp.2024.112478
Relationship Between Iron Deficiency and Severity of Tuberculosis: Influence on T Cell Subsets (2024) iScience. 10.1016/j.isci.2024.111709
CXCL10 May Be Responsible for Susceptibility to Pulmonary Embolism in COVID-19 Patients (2023) Journal of Inflammation Research. 10.2147/JIR.S431212
Diosmectite inhibits the interaction between SARS-CoV-2 and human enterocytes by trapping viral particles, thereby preventing NF-kappaB activation and CXCL10 secretion (2021) Scientific Reports. 10.1038/s41598-021-01217-2
Excessive Erythrophagocytosis Accounts for Systemic Inflammation in Chronic Kidney Disease (2024) Journal of Inflammation Research. 10.2147/JIR.S467136
APR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti–PD-1 efficacy in bladder cancer (2026) Scientific Reports. 10.1038/s41598-026-44653-8
Exploring alternative cytokines as potential biomarkers for latent tuberculosis infection in pregnant women (2022) PLoS One. 10.1371/journal.pone.0270552
USP18 promotes innate immune responses and apoptosis in influenza A virus-infected A549?cells via cGAS-STING pathway (2023) VIROLOGY. 10.1016/j.virol.2023.06.012
